{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eloctate+Prophylaxis",
    "query": {
      "intervention": "Eloctate Prophylaxis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T13:52:56.002Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02196207",
      "title": "Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Eloctate Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Eloctate ITI plus Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "Eloctate ITI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "4 Months to 99 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2020-08",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196207"
    },
    {
      "nct_id": "NCT03103542",
      "title": "Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant coagulation factor (rFVIIIFc)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 16,
      "start_date": "2017-08-29",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03103542"
    },
    {
      "nct_id": "NCT01458106",
      "title": "Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BIIB031 (rFVIIIFc)",
          "type": "DRUG"
        },
        {
          "name": "FVIII (PK subgroup only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "Up to 11 Years · Male only"
      },
      "enrollment_count": 71,
      "start_date": "2012-11",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01458106"
    },
    {
      "nct_id": "NCT04303559",
      "title": "The Hemophilia Inhibitor Prevention Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A Without Inhibitor"
      ],
      "interventions": [
        {
          "name": "Eloctate Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab Injection [Hemlibra]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "4 Years",
        "sex": "MALE",
        "summary": "4 Months to 4 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2021-10-11",
      "completion_date": "2022-06-16",
      "has_results": true,
      "last_update_posted_date": "2023-04-11",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04303559"
    },
    {
      "nct_id": "NCT02546622",
      "title": "ATHN 2: Factor Switching Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "American Thrombosis and Hemostasis Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 310,
      "start_date": "2015-09",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 27,
      "location_summary": "San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546622"
    },
    {
      "nct_id": "NCT02234323",
      "title": "An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "Up to 5 Years · Male only"
      },
      "enrollment_count": 108,
      "start_date": "2015-01-12",
      "completion_date": "2019-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-04-11",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234323"
    },
    {
      "nct_id": "NCT02586012",
      "title": "Weight-based Dosing in Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "rFVIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig Seaman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2015-09",
      "completion_date": "2020-01-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02586012"
    },
    {
      "nct_id": "NCT01454739",
      "title": "Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "0 Years and older · Male only"
      },
      "enrollment_count": 240,
      "start_date": "2011-12",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 22,
      "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01454739"
    },
    {
      "nct_id": "NCT02502149",
      "title": "Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2015-08",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02502149"
    },
    {
      "nct_id": "NCT04690322",
      "title": "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Factor VIII"
      ],
      "interventions": [
        {
          "name": "Eloctate",
          "type": "DRUG"
        },
        {
          "name": "Adynovate",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-04-15",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-05T13:52:56.002Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04690322"
    }
  ]
}